Apremilast for the treatment of a liver disease or a liver function abnormality
AssigneeCelgene Corporation
InventorsDouglas Hough, Randall Stevens
Life of this patent
Estimating the term…
Abstract
Methods of treating, managing or preventing liver disease are disclosed. Specific methods encompass the administration of apremilast, alone or in combination with additional active agents or treatment regimens.
Claims34
A method of treating or managing a patient having fatty liver disease;
- hepatic fibrosis;
- hemochromatosis;
- acute porphyria;
- sclerosis cholangitis;
- cholestatic jaundice;
- primary biliary cirrhosis;
- Wilson's disease;
- or hepatic steatosis, wherein the method comprises orally administering to the patient an effective amount of stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable prodrug or salt thereof.
A method of treating or managing pruritus associated with a liver disease or a liver function abnormality, wherein the method comprises orally administering to a patient having a liver disease or a liver function abnormality an effective amount of the compound, wherein the compound is stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable prodrug or salt thereof.
Dependencies are inferred from the claim text.